#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

How to diagnose cardiac sarcoidosis?


Authors: Martina Doubková 1;  Roman Panovský 2,3
Authors‘ workplace: Klinika nemocí plicních a TBC LF MU a FN Brno, pracoviště Bohunice 1;  I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně 2;  Mezinárodní centrum klinického výzkumu FN u sv. Anny v Brně 3
Published in: Vnitř Lék 2018; 64(7-8): 729-733
Category: Reviews

Overview

Sarcoidosis is a systemic granulomatous disease of unknown etiology that can affect any organ including the heart. Clinical manifestations of heart disease are seen in about 5 % of patients, but histology shows a higher rate of heart involvement by sarcoidosis. Therefore, heart sarcoidosis is underdiagnosed because of clinically non-symptomatic course in some patients or physicians simply do not think about this heart involvement. Echocardiography, Holter monitoring, magnetic resonance imaging, positron emission tomography/computed tomography, thallium scintigraphy, and endomyocardial biopsy are methods of investigation when suspected of heart involvement by sarcoidosis. In particular, magnetic resonance has gained importance recently in the diagnosis of cardiac sarcoidosis.

Key words:

cardiac sarcoidosis – diagnostics – therapy


Sources

1. Hunninghake GW, Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16(2):149–173.

2. Bradley B, Branley HM, Egan JJ et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63(Suppl 5): v1-v8. Dostupné z DOI: . Erratum in Thorax 2008; 63(11): 1029.

3. Bernstein M, Konzelmann F, Sidlick D. Boeck‘s sarcoid: report of a case with visceral involvement. Arch Intern Med 1929; 44: 721–734.

4. Matsui Y, Iwai I, Tachibana T et al. Clinico-pathological study on fatal myocardial sarcoidosis. Ann NY Acad Sci 1976; 278: 455–469.

5. Judson MA, Baughmann RP, Teirstein SS et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vas Diffuse Lung Dis 1999; 16(1): 75–86.

6. Padilla ML. Cardiac sarcoidosis. In: Baughman RP (ed). Sarcoidosis. Inform a Healthcare USA: New York 2010: 515–551.

7. Birnie DH, Sauer WH, Bogun F et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11(7): 1305–1323. Dostupné z DOI: .

8. Birnie DH, Nery PB, Ha AC et al. Cardiac Sarcoidosis. J Am Coll Cardiol 2016; 68(4): 411–421. Dostupné z DOI: .

9. Naruse TK, Matsuzawa Y, Ota M et al. HLA.DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens 2000; 56(1): 52–57.

10. Takashige N, Naruse TK, Matsumori A et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 1999; 54(2): 191–193.

11. Ungprasert P, Crowson CS, Matteson EL. Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013. Eur Respir J 2017; 49(2. pii: 1601290. Dostupné z DOI: .

12. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48(1): 11–22. Dostupné z DOI: .

13. Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107(10): 1255–1262. Dostupné z DOI: .

14. Rajavashisth TB, Liao JK, Galis ZS et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999; 274(17): 11924–11929.

15. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hemostaseologie 2010; 30(1): 5–6, 8–9.

16. Suzuki T, Kanda T, Kubota S et al. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest 1994; 106(4): 1021–1024.

17. Kusano KF, Satomi K. Diagnosis and treatment of cardiac sarcoidosis. Heart 2016; 102(3): 184–190. Dostupné z DOI: .

18. Nery PB, Beanlands RS, Nair GM et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014; 25(8): 875–881. Dostupné z DOI: .

19. Nery PB, Ardle BA, Redpath CJ et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 2014; 37(3): 364–374. Dostupné z DOI: .

20. Žurková M, Lošťáková V, Kolek V et al. Postižení srdce jako primární projev sarkoidózy. Stud Pneumol Phthiseol 2017; 77(6): 227–233.

21. Mehta D, Lubith SA, Frankel Z et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133(6): 1426–1435. Dostupné z DOI: .

22. Lošťáková V, Kolek V, Vašáková M et al. Sarkoidóza (Doporučený postup diagnostiky, terapie a sledování vývoje onemocnění. Dostupné z WWW: .

23. Bakker AL, Grutters JC, Keijsers RG et al. Cardiac sarcoidosis: challenges in clinical practice. Curr Opin Pulm Med 2017; 23(5): 468–475. Dostupné z DOI: .

24. Ohira H, Tsujino I, Ishimaru S et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35: 933–941.

25. Jeudy J, Burke AP, White CS et al. Cardiac sarcoidosis: the challenge of radiologic-pathologic correlation: from the radiologic pathology archives. Radiographics 2015; 35(3): 657–679. Dostupné z DOI: .

26. Smedema JP, Snoep G, van Kroonenburgh MP et al. Evaluation of the accuracy of gadolinium – enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45(10): 1683–1690. Dostupné z DOI: .

27. Bennett MK, Gilotra NA, Harrington C et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000–2009. Circ Heart Fail 2013; 6(4): 676–684. Dostupné z DOI: .

28. Yasaki Y, Isobe M, Hiroe M et al. For the Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients wit cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88(9): 1006–1010.

29. Sadek MM, Yung D, Birnie DH et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review, Am J Cardiol 2013; 29(9): 1034–1041. Dostupné z DOI: .

30. Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med 2015; 3(10): 813–822. Dostupné z DOI: .

31. Baughman RP, Sharma OP, Lynch JP. Sarcoidosis: is therapy effective? Semin Respir Infect 1998; 13(3): 255–273.

32. Siltzbach LE, James DG, Neville E et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57(6): 847–852.

33. Selkiguchi M, Hiroe M, Také M et al. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. II. Myocarditis. Jpn Circ J 1980; 44(4): 264–273.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#